Evercore Increases Humana (NYSE:HUM) Price Target to $195.00

Humana (NYSE:HUM) had its target price raised by investment analysts at Evercore from $180.00 to $195.00 in a research note issued on Wednesday,MarketScreener reports. Evercore’s price target points to a potential downside of 1.39% from the company’s current price.

Several other equities analysts also recently commented on the stock. Cantor Fitzgerald cut their price target on shares of Humana from $290.00 to $201.00 and set a “neutral” rating on the stock in a report on Thursday, February 12th. UBS Group reiterated a “neutral” rating on shares of Humana in a report on Wednesday, February 25th. JPMorgan Chase & Co. cut their price target on shares of Humana from $274.00 to $180.00 and set a “neutral” rating on the stock in a report on Friday, February 13th. Weiss Ratings reiterated a “sell (d+)” rating on shares of Humana in a report on Thursday, January 22nd. Finally, TD Cowen cut their price target on shares of Humana from $260.00 to $173.00 and set a “hold” rating on the stock in a report on Friday, February 13th. Seven analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $223.78.

Humana Stock Performance

Humana stock opened at $197.75 on Wednesday. The company’s 50-day moving average price is $180.61 and its 200-day moving average price is $233.42. Humana has a twelve month low of $163.11 and a twelve month high of $315.35. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 0.70. The company has a market cap of $23.74 billion, a PE ratio of 20.14, a price-to-earnings-growth ratio of 2.12 and a beta of 0.44.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.01) by $0.05. Humana had a net margin of 0.92% and a return on equity of 11.43%. The firm had revenue of $32.64 billion for the quarter, compared to the consensus estimate of $32.08 billion. During the same period in the previous year, the firm posted ($2.16) EPS. The business’s quarterly revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, equities research analysts forecast that Humana will post 16.47 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Sanjay K. Shetty bought 810 shares of the company’s stock in a transaction on Monday, February 23rd. The shares were acquired at an average cost of $185.21 per share, for a total transaction of $150,020.10. Following the purchase, the insider directly owned 11,657 shares of the company’s stock, valued at approximately $2,158,992.97. The trade was a 7.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Humana

A number of hedge funds have recently added to or reduced their stakes in the stock. Montag A & Associates Inc. lifted its position in shares of Humana by 1,880.0% in the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after purchasing an additional 94 shares during the period. CoreCap Advisors LLC lifted its position in shares of Humana by 54.4% in the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after purchasing an additional 37 shares during the period. Fideuram Asset Management Ireland dac purchased a new stake in shares of Humana in the 4th quarter worth approximately $27,000. Reflection Asset Management purchased a new stake in shares of Humana in the 4th quarter worth approximately $29,000. Finally, Rosenberg Matthew Hamilton lifted its position in shares of Humana by 136.0% in the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after purchasing an additional 68 shares during the period. 92.38% of the stock is currently owned by institutional investors.

Humana News Summary

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CMS finalizing a 2027 Medicare Advantage payment increase (about 2.48%) drove a broad relief rally for MA-focused insurers, supporting Humana’s valuation and momentum as investors priced in better margins/revenues for 2027. Humana Surges Above 50-Day MA
• Positive Sentiment: Humana has gone live with b.well and announced partnerships (Noom, Welldoc) to expand health data interoperability and digital care connections — a strategic push that can lower care costs, improve member engagement, and support MA growth. Humana Goes Live with b.well
• Positive Sentiment: Humana launched a value‑based pharmacist quality rewards program in Ohio to improve chronic‑condition outcomes (hypertension, diabetes) — a cost-control and quality initiative that aligns with payor incentives and could reduce utilization over time. Pharmacist Quality Rewards Program
• Positive Sentiment: Analyst activity has been constructive this week (upgrades, bullish price‑talk such as a Wells Fargo note highlighting upside), which supported the earlier price surge. Wells Fargo Forecasts Strong Price Appreciation
• Neutral Sentiment: Unusually large options activity was reported, indicating heightened speculative or hedging flows; this can amplify intraday moves but doesn’t necessarily change fundamentals. Unusually Large Options Trading
• Neutral Sentiment: Coverage pieces and screens are debating whether HUM is still “out of favor” after the rebound — useful for sentiment checks but not an immediate fundamental driver. Is Humana Still Out Of Favor?
• Negative Sentiment: Analysts expect Humana’s upcoming Q1 results to show a double‑digit EPS drop, creating short‑term earnings risk that likely contributed to profit‑taking after the rally. Ahead of Earnings Release
• Negative Sentiment: After a sharp multi‑day gain, intraday volume was lower and some investors appear to be locking in gains; that rotation / volatility around an earnings event can push shares down even with positive long‑term catalysts. Humana Moves 7.9% Higher

About Humana

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.